Related Experiment Video
Updated: Dec 25, 2025
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
885
Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations
Erik Anderson1, Richard Furie2
1Elmezzi Graduate School of Molecular Medicine, Feinstein Institutes for Medical Research, Northwell Health, 350 Community Drive, Manhasset, NY 11030, USA.
Immunotherapy
|April 3, 2020
Summary
Anifrolumab, a novel therapy targeting type I interferon, shows promise for treating systemic lupus erythematosus (SLE). Further research is needed to identify the ideal patient subgroups for this autoimmune disease treatment.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease with significant unmet therapeutic needs.
- Type I interferon (IFN) is a key factor implicated in SLE pathogenesis.
- Developing effective therapies for SLE is challenging due to disease heterogeneity.
Purpose of the Study:
- To review the clinical efficacy and safety of anifrolumab, a type I IFN receptor antagonist.
- To discuss the potential for anifrolumab as a future treatment for SLE.
- To explore challenges in identifying optimal patient subgroups for anifrolumab therapy.
Main Methods:
- Review of Phase III clinical trial data for anifrolumab in moderate-to-severe SLE patients.
- Analysis of clinical efficacy endpoints.
- Assessment of safety and tolerability profiles.
Main Results:
- Anifrolumab demonstrated clinical efficacy in treating moderate-to-severe SLE.
- The safety and tolerability of anifrolumab were evaluated in clinical trials.
- Identifying specific patient subgroups responsive to anifrolumab is an ongoing area of investigation.
Conclusions:
- Anifrolumab represents a promising therapeutic option for SLE by targeting the type I IFN pathway.
- Understanding patient heterogeneity is crucial for optimizing anifrolumab treatment outcomes.
- Further studies are warranted to refine patient selection for anifrolumab therapy.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
384
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
384
01:29Inflammatory Bowel Disease IV: Pharmacological Management
384
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
384
01:19Antiasthma Drugs: Leukotriene Modifiers
1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.6K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
392
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
392
01:17Drugs Used in Lower Respiratory Disorders: Overview
931
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
931
01:20Asthma: Pathogenesis and Management
1.1K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K